Branebrutinib

DRUG4 trials

Sponsors

Bristol-Myers Squibb

Conditions

Autoimmune DisorderDermatitis, AtopicHealthy ParticipantsHealthy VolunteersPrimary Sjögren's SyndromeRheumatoid ArthritisSystemic Lupus Erythematosus

Phase 1

Study to Assess the Effect of Branebrutinib on the Drug Levels of Rosuvastatin in Healthy Participants

CompletedNCT04515628

Bristol-Myers SquibbHealthy Participants

Start: 2020-08-02End: 2020-10-26Updated: 2022-03-10

A Study to Assess Relative Bioavailability of Branebrutinib, From a Tablet Formulation to the Capsule Formulation, the Effect of Food on the Bioavailability of Branebrutinib From a Tablet Formulation, and the Safety and Drug Levels of Branebrutinib From a Tablet Formulation in Healthy Participants

CompletedNCT05303220

Bristol-Myers SquibbHealthy Volunteers

Start: 2022-04-08End: 2022-08-18Updated: 2023-02-15

Phase 2

Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid Arthritis

CompletedNCT04186871

Bristol-Myers SquibbAutoimmune Disorder, Primary Sjögren's Syndrome, Rheumatoid Arthritis +1

Start: 2020-01-07End: 2022-12-05Updated: 2024-01-16

A Study of BMS-986166 or Branebrutinib for the Treatment of Participants With Atopic Dermatitis

CompletedNCT05014438

Bristol-Myers SquibbDermatitis, Atopic

Start: 2021-08-17End: 2022-08-22Updated: 2023-10-18